Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review

Clinical Reviews in Allergy and Immunology

Volumn 52, Issue 1, 2017, Pages 20-33

  Tiniakou, Eleni ^a   Mammen, Andrew L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Idiopathic inflammatory myopathies; Malignancy; Myositis specific antibodies

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CREATINE KINASE; DNA DIRECTED RNA POLYMERASE III; HLA A28 ANTIGEN; HLA ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE ANTIBODY; JO 1 ANTIBODY; MYOSITIS SPECIFIC ANTIBODY; NUCLEAR MATRIX PROTEIN 2 ANTIBODY; NUCLEAR PROTEIN TRANSCRIPTION GAMMA ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

AGE; AUTOIMMUNITY; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DYSPHAGIA; ERYTHROCYTE SEDIMENTATION RATE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNE MEDIATED NECROTIZING MYOPATHY; INCLUSION BODY MYOSITIS; MALIGNANT NEOPLASM; META ANALYSIS (TOPIC); MUSCLE BIOPSY; MUSCLE DISEASE; MYOSITIS; PATHOGENESIS; POLYMYOSITIS; PROGNOSIS; REVIEW; RISK FACTOR; SELECTION BIAS; SKIN NECROSIS; SMOKING; SYSTEMATIC REVIEW (TOPIC); VASCULITIS; IMMUNOLOGY; NEOPLASMS;

AUTOANTIBODIES; AUTOANTIGENS; HUMANS; MYOSITIS; NEOPLASMS; RISK FACTORS;

EID: 84944691588     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-015-8511-x     Document Type: Review

References (147)

1. Mammen AL (2010) Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 1184:134–53
2. Rider LG, Miller FW (2011) Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305(2):183–90
3. Sterz G (1916) Polymyositis. Berl Klin Wochenschr 53:489
4. Kankelheit H (1916) Uber primare nichteitrige Polymyositis. Dtsch Arch Klin Med 120:335–49
5. Troyanov Y et al (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84(4):231–49
6. Love LA et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70(6):360–74
7. Chinoy H et al (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66(10):1345–9
8. Targoff IN (2006) Myositis specific autoantibodies. Curr Rheumatol Rep 8(3):196–203
9. Gunawardena H, Betteridge ZE, McHugh NJ (2009) Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 48(6):607–12
10. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–7
11. Baer AN (2011) Paraneoplastic muscle disease. Rheum Dis Clin North Am 37(2):185–200, v-vi
12. Zahr ZA, Baer AN (2011) Malignancy in myositis. Curr Rheumatol Rep 13(3):208–15
13. Limaye V et al (2013) The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 33(4):965–71
14. Airio A, Pukkala E, Isomaki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22(7):1300–3
15. So MW et al (2011) Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol 38(11):2432–5
16. Antiochos BB et al (2009) Malignancy is associated with dermatomyositis but not polymyositis in Northern New England. USA J Rheumatol 36(12):2704–10
17. Yang Z et al (2015) Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42(2):282–91
18. Sigurgeirsson B et al (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326(6):363–7
19. Chow WH et al (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6(1):9–13
20. Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85(1):41–5
21. Miller FW et al (2003) Diagnostic criteria for polymyositis and dermatomyositis. Lancet 362(9397):1762–3, author reply 1763
22. Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362(9388):971–82
23. Buchbinder R et al (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134(12):1087–95
24. Buchbinder R, Hill CL (2002) Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 4(5):415–26
25. Chen YJ et al (2010) Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 12(2):R70
26. Maoz CR et al (1998) High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 27(5):319–24
27. Andras C et al (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35(3):438–44
28. Hill CL et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96–100
29. Ungprasert P et al (2013) Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in asian population. ISRN Rheumatol 2013:509354
30. Marie I et al (2012) Hematological malignancy associated with polymyositis and dermatomyositis. Autoimmun Rev 11(9):615–20
31. Mebazaa A et al (2011) Dermatomyositis and breast cancer: a multicenter Tunisian retrospective study of 13 cases. Tunis Med 89(1):18–22
32. Mordel N et al (1988) Concurrence of ovarian cancer and dermatomyositis. A report of two cases and literature review. J Reprod Med 33(7):649–55
33. Wang J et al (2013) Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 169(4):838–47
34. Gallais V, Crickx B, Belaich S (1996) Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Ann Dermatol Venereol 123(11):722–6
35. Basset-Seguin N et al (1990) Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol 126(5):633–7
36. Prohic A et al (2009) Clinical and biological factors predictive of malignancy in dermatomyositis. J Eur Acad Dermatol Venereol 23(5):591–2
37. Fardet L et al (2010) Frequency, clinical features and prognosis of cutaneous manifestations in adult patients with reactive haemophagocytic syndrome. Br J Dermatol 162(3):547–53
38. Feldman D et al (1983) Cutaneous vasculitis in adult polymyositis/dermatomyositis. J Rheumatol 10(1):85–9
39. Hunger RE, Durr C, Brand CU (2001) Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology 202(2):123–6
40. Fain O et al (2007) Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 57(8):1473–80
41. Lu X et al (2014) Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One 9(4):e94128
42. Ponyi A et al (2005) Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 1051:64–71
43. Leow YH, Goh CL (1997) Malignancy in adult dermatomyositis. Int J Dermatol 36(12):904–7
44. Uchino M et al (2013) Muscle biopsy findings predictive of malignancy in rare infiltrative dermatomyositis. Clin Neurol Neurosurg 115(5):603–6
45. Barona P et al (1993) Study of HLA antigens in patients with osteosarcoma. Hum Hered 43(5):311–4
46. Abrahamova J, Majsky A, Koutecky J (1981) HLA-antigens in germ cell tumors of various sites. Onkologie 4(1):19–20
47. Hornmark-Stenstam B, Landberg T, Low B (1978) HLA antigens in Hodgkin's disease of very long survival. Acta Radiol Oncol Radiat Phys Biol 17(4):283–8
48. Yang Y et al (2001) Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 21(3):106–11
49. Rose C et al (1994) Predictive signs of cancers in dermatomyositis. Study of 29 cases. Rev Med Interne 15(1):19–24
50. Park J et al (2001) Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 17(6):1216–9
51. Li J et al (2014) Idiopathic pulmonary fibrosis will increase the risk of lung cancer. Chin Med J (Engl) 127(17):3142–9
52. Hubbard R et al (2000) Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 161(1):5–8
53. Mileti LM et al (2009) Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol 15(5):254–5
54. Castaneda-Pomeda M, Prieto-Gonzalez S, Grau JM (2011) Antisynthetase syndrome and malignancy: our experience. J Clin Rheumatol 17(8):458
55. Marie I et al (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11(10):739–45
56. Neri R et al (2014) Cancer-associated myositis: a 35-year retrospective study of a monocentric cohort. Rheumatol Int 34(4):565–9
57. Legault D et al (2008) Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol 35(1):169–71
58. Watkins J et al (2004) Jo-1 syndrome with associated poorly differentiated adenocarcinoma. Rheumatology (Oxford) 43(3):389–90
59. Gunawardena H et al (2009) Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 60(6):1807–14
60. Espada G et al (2009) Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 36(11):2547–51
61. Ichimura Y et al (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71(5):710–3
62. Bodoki L et al (2014) Four dermatomyositis-specific autoantibodies-anti-TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 13(12):1211–9
63. Ceribelli A et al (2012) Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 14(2):R97
64. Casciola-Rosen L, Mammen AL (2012) Myositis autoantibodies. Curr Opin Rheumatol 24(6):602–8
65. Fiorentino DF et al (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 65(11):2954–62
66. Targoff IN et al (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54(11):3682–9
67. Kaji K et al (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46(1):25–8
68. Targoff IN et al (2006) Autoantibodies to transcriptional intermediary factor 1-garnma (TIF1-g) in dermatomyositis. Arthritis Rheum 54(9):S518–S518
69. Fujimoto M et al (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64(2):513–522
70. Ohashi M et al (2011) Anti-p155/140 antibody-positive dermatomyositis with metastasis originating from an unknown site. Acta Derm Venereol 91(1):84–5
71. Hoshino K et al (2010) Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 49(9):1726–33
72. Fujikawa K et al (2009) Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 38(4):263–267
73. Trallero-Araguas E et al (2012) Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis. Arthritis Rheum 64(2):523–532
74. Christopher-Stine L et al (2010) A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62(9):2757–66
75. Mammen AL et al (2011) Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63(3):713–21
76. . Limaye V, et al. (2014) Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve.
77. Pari Basharat AL, Andrew L Mammen, Iago Pinal-Fernandez, Tanmayee Bichile, Thomas E Lloyd, Sonye K. Danoff, Livia Casciola-Rosen and Lisa Christopher-Stine, Diabetes and Atorvastatin Are Potential Risk Factors for Statin-Associated Myopathy with Autoantibodies Against 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase, in American College of Rheumatology Meeting2014: Boston, USA
78. Yves Allenbach, J.K., Nicolas Champtiax, Aurelie Grados, Yoland Schoindre, Aude Rigolet, Kuberaka Mariampillai, Lucil Musset, Baptiste Hervier, Olivier Benveniste (2015) Cancer and necrotizing immune myopathy: high incidence in anti-HMGCR positive and seronegative patients but not in anti-SRP positive patients, in First international conference on myositis2015: Stockholm, Sweden.
79. Yoshimura N et al (1988) A case of chronic myositis associated with rimmed vacuole formation and hepatocellular carcinoma--on the entity of inclusion body myositis. Rinsho Shinkeigaku 28(1):55–61
80. Alexandrescu DT et al (2005) Steroid-responsive inclusion body myositis associated with endometrial cancer. Clin Exp Rheumatol 23(1):93–6
81. Talanin NY et al (1999) Dermatomyositis with the features of inclusion body myositis associated with carcinoma of the bladder. Br J Dermatol 141(5):926–30
82. Jensen ML et al (1997) Inclusion body myositis and transitional cell carcinoma of the bladder: significant resolution of symptoms after tumor excision. Arch Phys Med Rehabil 78(3):327–9
83. Arnardottir S et al (2001) Report of a patient with inclusion body myositis and CD8+ chronic lymphocytic leukaemia--post-mortem analysis of muscle and brain. Acta Neurol Scand 103(2):131–5
84. Beck EH, Amato AA, Greenberg SA (2014) Inclusion body myositis and chronic lymphocytic leukemia: a case series. Neurology 83(1):98–9
85. Wakata N et al (2002) Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41(11):729–34
86. Masuda H, Urushibara M, Kihara K (2003) Successful treatment of dermatomyositis associated with adenocarcinoma of the prostate after radical prostatectomy. J Urol 169(3):1084
87. Yoshinaga A et al (2005) Successful cure of dermatomyositis after treatment of nonseminomatous testicular cancer. Int J Urol 12(6):593–5
88. Bonnetblanc JM, Bernard P, Fayol J (1990) Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica 180(4):212–6
89. Tallai B et al (2006) Prostate cancer underlying acute, definitive dermatomyositis: successful treatment with radical perineal prostatectomy. Clin Rheumatol 25(1):119–20
90. Solomon SD, Maurer KH (1983) Association of dermatomyositis and dysgerminoma in a 16-year-old patient. Arthritis Rheum 26(4):572–3
91. Cherin P et al (1993) Dermatomyositis and ovarian cancer: a report of 7 cases and literature review. J Rheumatol 20(11):1897–9
92. Whitmore SE, Rosenshein NB, Provost TT (1994) Ovarian cancer in patients with dermatomyositis. Medicine (Baltimore) 73(3):153–60
93. Whitmore SE et al (1997) Serum CA-125 screening for ovarian cancer in patients with dermatomyositis. Gynecol Oncol 65(2):241–4
94. Amoura Z et al (2005) Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 14(5):1279–82
95. Wong RC et al (2002) Transient elevation of the tumor markers CA 15-3 and CASA as markers of interstitial lung disease rather than underlying malignancy in dermatomyositis sine myositis. J Clin Rheumatol 8(4):204–7
96. Selva-O'Callaghan A et al (2010) Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 123(6):558–62
97. Owada T et al (2012) Detection of inflammatory lesions by f-18 fluorodeoxyglucose positron emission tomography in patients with polymyositis and dermatomyositis. J Rheumatol 39(8):1659–65
98. Joseph CG et al (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343(6167):152–7
99. Shah AA et al (2010) Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62(9):2787–95
100. Le Gallo M et al (2012) Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 44(12):1310–5
101. Casciola-Rosen L et al (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201(4):591–601
102. Mammen AL et al (2009) Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 60(12):3784–93
103. Levine SM (2006) Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 18(6):620–4
104. Kasuya A et al (2013) TIF1 gamma-overexpressing, Highly Progressive Endometrial Carcinoma in a Patient with Dermatomyositis Positive for Malignancy-associated Anti-p155/140 Autoantibody. Acta Derm Venereol 93(6):715–716
105. Bohan A et al (1977) Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 56(4):255–86
106. Vesterager L, Worm AM, Thomsen K (1980) Dermatomyositis and malignancy. Clin Exp Dermatol 5(1):31–5
107. Callen JP et al (1980) The relationship of dermatomyositis and polymyositis to internal malignancy. Arch Dermatol 116(3):295–8
108. Goh CL, Rajan VS (1983) Dermatomyositis in a skin clinic. Ann Acad Med Singapore 12(1):6–12
109. Hoffman GS et al (1983) Presentation, Treatment, and Prognosis of Idiopathic Inflammatory Muscle Disease in a Rural Hospital. Am J Med 75(3):433–438
110. Benbassat J et al (1985) Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 28(3):249–55
111. Manchul LA et al (1985) The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med 145(10):1835–9
112. Tymms KE, Webb J (1985) Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 12(6):1140–8
113. Holden DJ, Brownell AK, Fritzler MJ (1985) Clinical and serologic features of patients with polymyositis or dermatomyositis. Can Med Assoc J 132(6):649–53
114. Chan HL (1985) Dermatomyositis and cancer in Singapore. Int J Dermatol 24(7):447–50
115. Baron M, Small P (1985) Polymyositis/dermatomyositis: clinical features and outcome in 22 patients. J Rheumatol 12(2):283–6
116. Hochberg MC, Feldman D, Stevens MB (1986) Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 15(3):168–78
117. Lakhanpal S et al (1986) Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 61(8):645–53
118. Ponge A et al (1987) Para-Neoplastic Dermatomyositis-Polymyositis. Revue De Medecine Interne 8(3):251–256
119. Cox NH et al (1990) Dermatomyositis. Disease associations and an evaluation of screening investigations for malignancy. Arch Dermatol 126(1):61–5
120. Prasad ML et al (1992) Idiopathic inflammatory myopathy—clinicopathological observations in the Indian population. Br J Rheumatol 31(12):835–839
121. Koh ET et al (1993) Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 52(12):857–61
122. Selvaag E, Thune P, Austad J (1994) Dermatomyositis and cancer. A retrospective study. Tidsskr Nor Laegeforen 114(20):2378–80
123. Dawkins MA et al (1998) Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol 38(3):397–404
124. Dourmishev LA (1999) Dermatomyositis associated with malignancy. 12 case reports. Adv Exp Med Biol 455:193–9
125. Ang P, Sugeng MW, Chua SH (2000) Classical and amyopathic dermatomyositis seen at the National Skin Centre of Singapore: a 3-year retrospective review of their clinical characteristics and association with malignancy. Ann Acad Med Singapore 29(2):219–23
126. Chen YJ, Wu CY, Shen JL (2001) Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 144(4):825–31
127. Amerio P et al (2002) Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis. Eur J Dermatol 12(2):165–9
128. Louthrenoo W et al (2002) Serum muscle enzymes, muscle pathology and clinical muscle weakness: correlation in Thai patients with polymyositis/dermatomyositis. J Med Assoc Thai 85(1):26–32
129. Porkodi R et al (2002) Clinical spectrum of inflammatory myositis in South India--a ten year study. J Assoc Physicians India 50:1255–8
130. Sparsa A et al (2002) Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 138(7):885–90
131. Mebazaa A et al (2003) Dermatomyositis and malignancy in Tunisia: a multicenter national retrospective study of 20 cases. J Am Acad Dermatol 48(4):530–4
132. Burnouf M et al (2003) Cutaneous necrosis is predictive of cancer in adult dermatomyositis. Ann Dermatol Venereol 130(3):313–6
133. Kang EH et al (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 44(10):1282–6
134. Lee SW et al (2006) Malignancies in Korean patients with inflammatory myopathy. Yonsei Med J 47(4):519–23
135. Tani K et al (2007) Comparison of clinical course of polymyositis and dermatomyositis: a follow-up study in Tokushima University Hospital. J Med Invest 54(3-4):295–302
136. Mustafa KN, Dahbour SS (2010) Clinical characteristics and outcomes of patients with idiopathic inflammatory myopathies from Jordan 1996-2009. Clin Rheumatol 29(12):1381–5
137. Kuo CF et al (2011) Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 165(6):1273–9
138. Azuma K et al (2011) Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 21(2):178–83
139. Shu XM et al (2011) Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China. BMC Neurol 11:143
140. Teh CL, Wong JS, Soo HH (2012) Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital. Rheumatol Int 32(1):265–8
141. Mok CC et al (2012) Standardized Incidence Ratios and Predictors of Malignancies in 215 Southern Chinese Patients with Inflammatory Myopathies. Arthritis Rheum 64(10):S96–S96
142. Chen D et al (2014) Incidence and predictive factors for malignancies with dermatomyositis: a cohort from southern China. Clin Exp Rheumatol 32(5):615–21
143. Ortigosa LC, Reis VM (2014) Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clinicas (HCFMUSP), Sao Paulo. Brazil An Bras Dermatol 89(5):719–27
144. Danieli MG et al (2014) Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev 13(10):1048–54
145. Marie I et al (1999) Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 78(3):139–47
146. Selva-O'Callaghan A et al (2002) The neural network as a predictor of cancer in patients with inflammatory myopathies. Arthritis Rheum 46(9):2547–8
147. Requena C et al (2014) Paraneoplastic dermatomyositis: a study of 12 cases. Actas Dermosifiliogr 105(7):675–82